Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people with non-muscle invasive bladder cancer (NMIBC). With bladde






